17th February 2025
News
Sygnature Discovery boosts growth of its In Vivo Pharmacology business with appointment of new Vice President
12th February 2025
News
Sygnature Discovery Appoints New Chief Commercial Officer to Drive Next Phase of Business Growth
23rd January 2025
News
Sygnature Discovery appoints Rick Davies to spearhead growth as Director of its UK Protein Sciences and Structural Biology business (formerly, Peak Proteins)
9th October 2024
News
Sygnature Discovery has Chosen Elsevier as New Preferred Partner to Empower its Global Team of Chemists
3rd October 2024
News
Sygnature Discovery Strengthens Leadership Team with Amira Modi as Chief Operating Officer and Board Member
26th September 2024
News
Sygnature Discovery Unlocks Life-Changing Treatment Options with New Human Disease Modeling Platform
20th August 2024
News
Sygnature Discovery boosts North American growth with new General Manager
30th April 2024
News
Sygnature Discovery Receives EcoVadis Award For Sustainable Excellence
23rd April 2024
News
Sygnature Discovery goes for global industry recognition with Chief Scientific Officer hire
29th November 2023
News
First patients dosed in Phase 1a clinical trial of UCL-backed G-Quadruplex (G4) targeting treatment for solid tumors, including pancreatic cancer
13th November 2023
News
Sygnature Discovery Appoints Industry Leaders To Board Of Directors
2nd November 2023
News
Sygnature Discovery invests £3.75M in Compound Management to provide cutting-edge hit finding capabilities to pharma and biotechnology customers